Department of Biostatistics, University of North Carolina, McGavran-Greenberg Hall, CB#7420, Chapel Hill, NC, USA.
Biostatistics. 2019 Jul 1;20(3):400-415. doi: 10.1093/biostatistics/kxy009.
We consider the problem of Bayesian sample size determination for a clinical trial in the presence of historical data that inform the treatment effect. Our broadly applicable, simulation-based methodology provides a framework for calibrating the informativeness of a prior while simultaneously identifying the minimum sample size required for a new trial such that the overall design has appropriate power to detect a non-null treatment effect and reasonable type I error control. We develop a comprehensive strategy for eliciting null and alternative sampling prior distributions which are used to define Bayesian generalizations of the traditional notions of type I error control and power. Bayesian type I error control requires that a weighted-average type I error rate not exceed a prespecified threshold. We develop a procedure for generating an appropriately sized Bayesian hypothesis test using a simple partial-borrowing power prior which summarizes the fraction of information borrowed from the historical trial. We present results from simulation studies that demonstrate that a hypothesis test procedure based on this simple power prior is as efficient as those based on more complicated meta-analytic priors, such as normalized power priors or robust mixture priors, when all are held to precise type I error control requirements. We demonstrate our methodology using a real data set to design a follow-up clinical trial with time-to-event endpoint for an investigational treatment in high-risk melanoma.
我们考虑了在存在历史数据的情况下进行临床试验的贝叶斯样本量确定问题,这些数据可以提供有关治疗效果的信息。我们广泛适用的基于模拟的方法为校准先验的信息量提供了一个框架,同时确定了新试验所需的最小样本量,以便总体设计具有适当的能力来检测非零治疗效果和合理的 I 型错误控制。我们开发了一种全面的策略来获取零假设和替代抽样先验分布,这些分布用于定义贝叶斯对传统 I 型错误控制和功效概念的概括。贝叶斯 I 型错误控制要求加权平均 I 型错误率不超过预定阈值。我们开发了一种使用简单的部分借用功效先验生成适当大小的贝叶斯假设检验的程序,该先验总结了从历史试验中借用的信息量的分数。我们从模拟研究中得出的结果表明,当所有这些都符合精确的 I 型错误控制要求时,基于这种简单功效先验的假设检验程序与基于更复杂的荟萃分析先验(如归一化功效先验或稳健混合先验)的程序一样有效。我们使用真实数据集展示了我们的方法,以设计具有高风险黑色素瘤研究治疗的时间事件终点的后续临床试验。